AgingResearch.NewsJoin free

Phase 2Recruiting

Feasibility Trial for a Right Ventricular Failure Platform Trial (CRAVE)

Feasibility Trial for the Canadian Right Ventricular AdaptiVE (CRAVE) Platform for Therapies Targeting Right Ventricular Failure

Sponsor
University of Alberta (Academic or other)
Enrolment
30 planned
Conditions
Pulmonary Hypertension; Right Ventricular Dysfunction; Right Heart Failure
Interventions
Empagliflozin; Ranolazine
Ages
adults, older adults
Registry
NCT06570473

Full record on ClinicalTrials.gov

From the registry

The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.

Primary outcomes

  • The proportion of eligible participants approached that consent
  • The proportion of participants who consent that are randomized
  • Average enrolment rate of participants per centre per month
  • Loss of follow up or death

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered